Editas Medicine Inc (EDIT) CEO Sells $301,487.94 in Stock

Editas Medicine Inc (NASDAQ:EDIT) CEO Katrine Bosley sold 8,333 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $36.18, for a total transaction of $301,487.94. Following the sale, the chief executive officer now directly owns 1,338,898 shares of the company’s stock, valued at $48,441,329.64. The sale was disclosed in a document filed with the SEC, which is available through this link.

Katrine Bosley also recently made the following trade(s):

  • On Tuesday, January 30th, Katrine Bosley sold 20,000 shares of Editas Medicine stock. The shares were sold at an average price of $38.79, for a total transaction of $775,800.00.
  • On Tuesday, January 23rd, Katrine Bosley sold 3,338 shares of Editas Medicine stock. The shares were sold at an average price of $35.28, for a total transaction of $117,764.64.
  • On Wednesday, January 3rd, Katrine Bosley sold 14,995 shares of Editas Medicine stock. The shares were sold at an average price of $34.15, for a total transaction of $512,079.25.
  • On Friday, December 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The shares were sold at an average price of $29.58, for a total transaction of $246,490.14.

Editas Medicine Inc (NASDAQ:EDIT) traded down $0.77 during midday trading on Monday, hitting $33.98. The stock had a trading volume of 1,535,825 shares, compared to its average volume of 1,924,251. The company has a quick ratio of 10.12, a current ratio of 10.12 and a debt-to-equity ratio of 0.19. The company has a market cap of $1,576.36, a P/E ratio of -10.49 and a beta of 4.79. Editas Medicine Inc has a 52-week low of $13.12 and a 52-week high of $41.60.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Tuesday, November 7th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). The firm had revenue of $6.28 million for the quarter, compared to the consensus estimate of $2.66 million. Editas Medicine had a negative net margin of 1,127.03% and a negative return on equity of 70.19%. The firm’s revenue was up 553.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.59) earnings per share. equities analysts expect that Editas Medicine Inc will post -2.92 EPS for the current fiscal year.

A number of brokerages have issued reports on EDIT. BidaskClub raised shares of Editas Medicine from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 30th. SunTrust Banks raised shares of Editas Medicine from a “hold” rating to a “buy” rating and increased their price objective for the company from $17.00 to $45.00 in a report on Tuesday, January 23rd. Zacks Investment Research lowered shares of Editas Medicine from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. ValuEngine lowered shares of Editas Medicine from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Cann reaffirmed a “hold” rating on shares of Editas Medicine in a report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. Editas Medicine currently has an average rating of “Buy” and an average target price of $30.73.

Several hedge funds and other institutional investors have recently bought and sold shares of EDIT. IHT Wealth Management LLC bought a new position in shares of Editas Medicine during the 2nd quarter valued at approximately $107,000. Great West Life Assurance Co. Can boosted its position in shares of Editas Medicine by 519.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock valued at $114,000 after acquiring an additional 4,159 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Editas Medicine by 308.4% during the 2nd quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock valued at $145,000 after acquiring an additional 6,535 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Editas Medicine by 4.1% during the 2nd quarter. Royal Bank of Canada now owns 9,364 shares of the company’s stock valued at $157,000 after acquiring an additional 372 shares during the last quarter. Finally, Plancorp LLC bought a new position in shares of Editas Medicine during the 4th quarter valued at approximately $235,000. Hedge funds and other institutional investors own 64.45% of the company’s stock.

WARNING: “Editas Medicine Inc (EDIT) CEO Sells $301,487.94 in Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/05/editas-medicine-inc-edit-ceo-sells-301487-94-in-stock.html.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply